TNFRSF9 and neoplasm: A recent study has indicated that the combination of a TNFRSF9 agonist and PD-L1 (CD274) can effectively activate and amplify tumor-specific cytotoxic T cells to enhance tumor control and killing, suggesting that PGK1 may serve as a potential immunotherapy target or can enhance the anti-tumor effect of PD-L1 [54].